Prevalence, Awareness, Treatment, and Control Rate of Hypertension in HIV-Infected Patients: The HIV-HY Study

Prevalence, Awareness, Treatment, and Control Rate of Hypertension in HIV-Infected Patients: The HIV-HY Study

Por: Giuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, Giustino Parruti, Giacomo Pucci, Antonio Di Biagio, Leonardo Calza, Giancarlo Orofino, Laura Carenzi, Enisia Cecchini, Giordano Madeddu, Tiziana Quirino, Giuseppe Schillaci  for the CISAI study group.  American Journal of Hypertension, Volume 27 Issue 2, Pp. 222-228, February 2014.

We aimed to assess the prevalence of hypertension in an unselected human immunodeficiency virus (HIV)–infected population and to identify factors associated with hypertension prevalence, treatment, and control. Atherosclerotic cardiovascular disease (CVD), a leading cause of morbidity and mortality in the general population, is an increasing concern for human immunodeficiency virus (HIV)–infected patients. HIV-infected individuals are exposed to accelerated vascular aging,1 and this issue has become even more relevant since antiretroviral therapy has impressively extended the life span of HIV-infected individuals.